Evidence map›Paper›PMID 40411581›Full record

ArticleCancer immunology, immunotherapy : CII2025

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1.

Barry D Hock, Liping Goddard, Lachlan J Dobson, Sean A MacPherson, John L O'Donnell, Judith L McKenzie, Alexander D McLellan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Barry D HockHaematology Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. barry.hock@otago.ac.nz.
Liping GoddardHaematology Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Lachlan J DobsonDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Sean A MacPhersonHaematology Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
John L O'DonnellImmunology Department of Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand.
Judith L McKenzieHaematology Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Alexander D McLellanDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of blocking antibodies against programmed death-1 (PD-1) and its ligand (PD-L1) is modulated by signalling through their Fc regions. The Fc region of anti-PD-1/PD-L1 antibodies, when cell-bound, represents a potential target for recognition by circulating rheumatoid factor (RF) autoantibodies. The resultant cell-associated immune complex may then provide different Fc signals to that of the PD-1/PD-L1 antibodies alone. However, little is known regarding the interaction of RF and therapeutic PD-1/PD-L1 antibodies. We report that PD-1 (pembrolizumab, nivolumab) and PD-L1 (avelumab) antibodies, when bound to their cellular targets, are recognised by both IgM-RF and IgA-RF components of RF

Indexed as

Antibodies, MonoclonalB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorRheumatoid FactorAnimalsAntibodies, Monoclonal, HumanizedHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedavelumabB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorRheumatoid FactorAntibodyFc receptorPD-1PD-L1Rheumatoid factor

Identifiers

PMID40411581
PMCPMC12103427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.